Description: Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
Home Page: ambrx.com
AMAM Technical Analysis
10975 North Torrey Pines Road
La Jolla,
CA
92037
United States
Phone:
858 875 2400
Officers
| Name | Title |
|---|---|
| Ms. Sonja Nelson CPA | Chief Financial & Operating Officer |
| Mr. Daniel J. O'Connor J.D. | CEO, Pres & Director |
| Dr. Ying J. Buechler Ph.D. | Chief Technology Officer |
| Dr. Shawn Shao-Hui Zhang Ph.D. | Chief Scientific Officer |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.2363 |
| Price-to-Book MRQ: | 0.1116 |
| Price-to-Sales TTM: | 16.5982 |
| IPO Date: | 2021-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 81 |